Loading…
Employees: 466
Size Sun Pharma Advanced Research (SPARC.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $665M, the 739th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹193.52 on 6 Nov 2026.
Performance Over six months the shares gained 16.0%, against -8.8% for the median peer and 0.0% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 3,141.0% over the last twelve months (peer median +10.1%); the operating margin is 84.3% (peer median 4.8%).
Valuation It trades at 2.6× enterprise value to sales against a peer median of 2.7× (9th cheapest of 17).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹19.3B | ₹18.8B | ₹718M | ₹755M | ₹2.39B |
| Revenue growth | — | +2,518% | -5% | -68% | — |
| Gross profit | ₹17.8B | ₹17.1B | -₹1.34B | -₹1.24B | ₹821M |
| EBITDA | ₹16.4B | ₹16.1B | -₹3.22B | -₹3.99B | -₹2.12B |
| Net income | ₹16.4B | ₹15.5B | -₹3.43B | -₹3.87B | -₹2.23B |
| Free cash flow | n/a | -₹2.97B | -₹3.65B | -₹4.35B | -₹904M |
| Capital expenditure | n/a | ₹238M | ₹103M | ₹265M | ₹154M |
| Total debt | ₹24.4M | ₹5.59B | ₹2.69B | ₹612M | ₹157M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SPARC.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.7% | -6.7% | 8th highest of 21 |
| 6-month return | +16.0% | -8.8% | 3rd highest of 21 |
| Distance from 52-week high | -33.0% | -32.7% | 11th highest of 21 |
| Revenue growth (TTM) | +3,141.0% | +10.1% | highest of 17 |
| Operating margin | 84.3% | 4.8% | highest of 17 |
| EV / Sales | 2.6× | 2.7× | 9th cheapest of 17 |
| EV / EBITDA | 3.0× | 12.7× | cheapest of 7 |
| Net debt / EBITDA | -0.8× | -1.0× | 4th least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sun Pharma Advanced Research SPARC.NS | India | $665M | +16% | +3,141% | 84% | 2.6× | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $664M | -26% | -10% | -9% | 2.2× | 0.3% | -17.9% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $666M | +10% | +40% | -65% | 19.0× | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $663M | -45% | +47% | 7% | 5.1× | n/a | n/a |
| Immix Biopharma IMMX | United States | $668M | -17% | n/a | n/a | n/a | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $661M | -25% | +2% | 4% | 1.4× | 1.1% | -1.6% |
| FDC FDC.NS | India | $672M | +4% | +10% | 14% | 2.5× | 25.9% | +10.3% |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $657M | -4% | -6% | 5% | 2.9× | 23.2% | +21.9% |
| Center Laboratories 4123.TWO | Taiwan | $676M | -28% | +4% | 5% | 13.6× | 50.8% | +16.2% |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $653M | -11% | -3% | -1% | 2.5× | 12.1% | -5.9% |
| Oneness Biotech 4743.TWO | Taiwan | $652M | -21% | +37% | -510% | 107.7× | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $678M | -6% | +10% | 19% | 2.5× | -2.4% | +6.4% |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 0.6× | -2.5% | -1.8% |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 4% | 6.2× | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 0.7× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 10.9× | 41.4% | +11.2% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 2.5× | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $641M | -51% | n/a | n/a | n/a | n/a | n/a |
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 3.4× | 0.0% | +51.6% |
| Achieve Life Sciences ACHV | United States | $692M | +29% | n/a | n/a | n/a | n/a | n/a |